Q1 EPS Forecast for Abeona Therapeutics Decreased by Analyst

Abeona Therapeutics Inc (NASDAQ:ABEO) – Research analysts at HC Wainwright decreased their Q1 2025 EPS estimates for Abeona Therapeutics in a research note issued on Monday, March 24th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will post earnings per share of ($0.36) for the quarter, down from their previous estimate of ($0.34). HC Wainwright currently has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Abeona Therapeutics’ Q3 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.13) EPS and FY2025 earnings at ($1.11) EPS.

Abeona Therapeutics (NASDAQ:ABEO) last posted its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.19.

A number of other brokerages have also issued reports on ABEO. Oppenheimer initiated coverage on shares of Abeona Therapeutics in a research report on Wednesday, March 5th. They issued an “outperform” rating and a $16.00 target price for the company. StockNews.com upgraded shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Monday. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $17.50.

Abeona Therapeutics Trading Down 2.3 %

NASDAQ:ABEO opened at $5.00 on Wednesday. The stock has a market cap of $217.36 million, a price-to-earnings ratio of -1.86 and a beta of 1.79. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.12 and a current ratio of 6.12. Abeona Therapeutics has a 1 year low of $3.05 and a 1 year high of $8.45. The business has a fifty day moving average of $5.43 and a 200-day moving average of $5.82.

Institutional Investors Weigh In On Abeona Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Twinbeech Capital LP bought a new position in shares of Abeona Therapeutics during the 4th quarter valued at about $58,000. Squarepoint Ops LLC bought a new stake in Abeona Therapeutics during the fourth quarter worth approximately $67,000. Jane Street Group LLC bought a new stake in Abeona Therapeutics during the third quarter worth approximately $84,000. Oxford Asset Management LLP acquired a new position in Abeona Therapeutics in the fourth quarter worth approximately $118,000. Finally, Charles Schwab Investment Management Inc. bought a new position in shares of Abeona Therapeutics in the third quarter valued at $151,000. 80.56% of the stock is currently owned by institutional investors.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.